<DOC>
	<DOCNO>NCT00693004</DOCNO>
	<brief_summary>A randomized placebo-controlled study evaluate efficacy PRX-03140 monotherapy subject Alzheimer 's disease . The study consist 3-month double-blind treatment period optional 3-month extension period .</brief_summary>
	<brief_title>Study PRX-03140 Monotherapy Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Men Women clinical diagnosis Probable AD MMSE score 16 24 inclusive Age &gt; 50 &lt; 90 year Brain CT MRI scan Consistent primary diagnosis AD within 12 month Neurological examination without focal deficit ( exclude change attributable peripheral nervous system disease , trauma congenital birth deficit ) No history evidence CNS disorder could interpret cause dementia No diagnosis vascular dementia No history significant psychiatric illness schizophrenia bipolar affective disorder . Subjects major depressive disorder stable dose antidepressant &gt; 6 month may eligible No evidence follow : current vitamin B12 deficiency , positive syphilis serology , positive HIV test , abnormality thyroid function No cognitive rehabilitation within 6 month study Subject regular caregiver willing attend study visit Signed informed consent subject ( legal guardian , applicable ) No history drug alcohol abuse No clinically significant laboratory abnormality medical history No investigational drug within 30 day Randomization Intolerance allergy cholinesterase inhibitor Can cholinesterase inhibitor AD &gt; 2 year If cholinesterase inhibitor &lt; 2 year , must discontinue &gt; = 2 month prior randomization Can receive memantine within 2 month No clinically significant ECG abnormality prior randomization No history uncontrolled seizure disorder within 12 month Can take MAO inhibitor , bupropion , fluoxetine , paroxetine , quinidine No history malignancy within 3 year randomization Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>